FDA Recalls Specific Lot of Xanax XR Due to Dissolution Failure: What Patients Need to Know

The U.S. Food and Drug Administration (FDA) has issued a voluntary recall for a specific lot of Xanax XR (alprazolam extended-release tablets) due to concerns over its effectiveness. The recall was initiated by Viatris Inc., a leading pharmaceutical company, after quality control testing revealed the tablets failed to meet dissolution specifications.

The affected product is the 3-milligram (mg) strength of Xanax XR, packaged in 60-tablet bottles. The recalled lot, identified by the number 8177156, has an expiration date of February 28, 2027. The tablets were produced in Ireland and distributed by Viatris Specialty LLC in Morgantown, West Virginia.

Key Details of the Recall

• Recall Initiation Date: March 17, 2025
• Affected Product: Xanax XR (alprazolam extended-release) 3mg tablets
• Packaging: 60-tablet bottles
• Lot Number: 8177156
• Expiration Date: February 28, 2027
• Manufacturer: Viatris Inc.
• Distribution: Nationwide in the United States

Why Was the Recall Issued?

Dissolution testing is a critical quality control measure that ensures medications release their active ingredients at the correct rate for optimal effectiveness. In this case, the recalled Xanax XR tablets failed to meet the FDA’s dissolution specifications, meaning they may not break down and release the medication as intended in the body.

Aleksey Aronov, AGPCNP-BC, a board-certified adult geriatric primary care nurse practitioner and founder/CEO of VIPs IV, explained the potential impact to Healthline:

“When a pill does not dissolve the right way, the body may not absorb the correct amount of the medicine, which may result in not treating anxiety or panic symptoms appropriately. Pills that fail to dissolve essentially may not be effective.”

The FDA classifies this recall as a Class II recall, indicating that the use of the affected medication could cause temporary or medically reversible adverse health consequences. However, the agency notes there is little risk of serious adverse health consequences.

Aronov further clarified that the issue is not a safety hazard and will not cause harm to the body. Instead, it is a quality control problem that may result in the medication not providing the intended therapeutic benefit.

What Should Patients Do?

Patients currently taking Xanax XR are advised to continue taking their medication until they can consult with their healthcare provider for further guidance. The FDA and Viatris urge patients to check their medication bottles for the following:

• Lot number: 8177156
• Expiration date: February 28, 2027
• Tablet strength: 3mg

If you have the affected lot, contact Viatris Customer Service or your healthcare provider to discuss alternative treatment options. Do not discontinue your medication without consulting a medical professional, as sudden cessation can lead to withdrawal symptoms or other complications.

No Safety Concerns, But Effectiveness May Be Compromised

The FDA emphasizes that while the recalled Xanax XR tablets may not be fully effective, they are not considered unsafe. The primary concern is that the medication may not provide the intended relief from anxiety or panic disorders due to improper dissolution.

For more information, patients and healthcare providers can refer to the FDA Enforcement Report or contact Viatris directly for assistance.